BACE2 and hyperphosphatemia: Particularly, in mouse AVFs with hyperphosphatemia, we found that BACE2 inhibition could rectify the sVEGFR3‐related VEGF‐C unresponsiveness in LECs, and normalized the lymphatic network to alleviate local inflammation and neointima formation.